Werner syndrome ATP-dependent helicase (WRN) is an enzyme involved in DNA replication and repair and has been identified as a synthetic lethality target in tumors with high microsatellite instability (MSI-H).
Microsatellite instability (MSI), which results from defects in the DNA mismatch repair system, is an important biomarker in colorectal cancer. While the MSI-high (MSI-H) status predicts response to pembrolizumab, a commonly used immune checkpoint inhibitor in metastatic colorectal cancer, a subset of MSI-H patients still does not respond to this treatment.
Suzhou Zion Pharma Technology Co. Ltd. has described transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) and/or probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer and viral infections.
Shanghai Ennova Biopharmaceutical Co. Ltd. has identified condensed ring compounds acting as ATP-dependent 6-phosphofructokinase, liver type (PFKL) activators reported to be useful for the treatment of cancer, autoimmune disease, inflammatory disorders, lung diseases, metabolic diseases, sepsis and thrombosis.
Gen1e Lifesciences Inc. and the University of Maryland have patented mitogen-activated protein kinase 1 (MAPK1; ERK2) and/or mitogen-activated protein kinase 3 (MAPK3; ERK1) inhibitors.
Esophageal cancer accounts for the sixth leading cause of cancer-related deaths worldwide. The clinical efficacy of therapies for esophageal squamous-cell carcinoma (ESCC) remain limited due to drug resistance and side effects. There is an urgent need to identify new therapeutic targets to shed light on its pathogenesis.
Pancreatic cancer is one of the deadliest malignancies, with a 5-year overall survival rate of only 13%. Earlier studies demonstrated that the Lister strain of oncolytic vaccinia virus (VVL) is capable of replicating and delivering therapeutic genes even under hypoxic conditions, highlighting its potential as a promising vector for targeting hypoxic tumors like pancreatic cancer.
CCR8 is highly expressed on immunosuppressive regulatory T cells (Tregs) in various solid tumors, making it a potential target to enhance antitumor immunity and the efficacy of cancer therapies, including checkpoint inhibitors. However, the impact of CCR8 expression on the Treg phenotype and its role in cancer progression remain unclear.
Merkel cell carcinoma is an aggressive skin carcinoma that, when advanced or metastatic, is typically treated with chemotherapy, which often leads to resistance.
RSS
